查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1179872

2023-2030 年糖尿病神經性足潰瘍的全球市場

Global Diabetic Neurotherapy Foot Ulcers Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

在預測期內（2023 年至 2030 年），糖尿病神經性足潰瘍市場規模預計將以 8.4% 的複合年增長率增長。

糖尿病性潰瘍是導致截肢的最常見腿部損傷。 全科醫生在早期發現和預防糖尿病足病方面發揮著至關重要的作用。 糖尿病足的管理需要深入了解主要的截肢危險因素、常規評估和細緻的預防性維護。 最常見的潰瘍風險因素包括外周動脈閉塞性疾病、足部結構畸形和糖尿病性神經病變。

市場動態

推動全球糖尿病足潰瘍市場的主要因素是糖尿病足潰瘍增加導致的市場擴張、治療技術進步引起的市場牽引以及特定類型足潰瘍的可用性。有一定的敷料。

由於糖尿病足潰瘍的增加，擴張正在加速。

糖尿病患者很容易患上糖尿病足潰瘍，這可能導致足部截肢。 接受胰島素治療的糖尿病患者更容易患足部潰瘍。 患有糖尿病、肥胖症以及腎臟、眼睛和心臟問題的人也可能患上糖尿病足潰瘍。 煙草和酒精的使用都被認為會增加患病的風險。

據美國國立衛生研究院估計，全球每年有 9.1 至 2610 萬糖尿病足潰瘍發生。 據估計，15-25% 的糖尿病患者一生中會患上糖尿病足潰瘍。 隨著每年有越來越多的人被診斷出患有糖尿病，糖尿病足潰瘍的患病率將不可避免地增加。 糖尿病足潰瘍可發生於任何年齡，但最常見於 45 歲以上的糖尿病患者。 大多數患有足部潰瘍的美國人是拉丁裔、非裔美國人和美洲原住民。 因此，糖尿病足潰瘍發病率的增加會加速生長。

成本密集型傷口護理產品和糖尿病神經性足潰瘍 (DME) 治療預計會阻礙市場增長。

糖尿病足潰瘍是糖尿病最常見的症狀，也是導致死亡的主要原因。 隨著細胞外蛋白、治療劑和其他選擇變得過於昂貴，替代療法的技術發展不斷加快預計將減緩市場增長。

COVID-19 影響分析

自 2019 年 12 月爆發 COVID-19 病毒以來，該病毒已傳播到超過 75 個國家，世界衛生組織已宣布進入公共衛生緊急狀態。 例如 例如，根據世界衛生組織的一項研究，截至 2021 年 7 月，全球約有 1.9 億人感染了冠狀病毒 (COVID-19)。

COVID-19 主要通過三種方式影響經濟：直接改變供需、擾亂分銷網絡以及對企業和金融市場產生經濟影響。 包括中國、印度、沙特阿拉伯、阿拉伯聯合酋長國和埃及在內的許多國家普遍實行封鎖，這使得將藥品從一個地方轉移到另一個地方變得困難重重。 此外，COVID-19大流行在各個方面對全球糖尿病足潰瘍治療市場的行業參與者構成了主要障礙。 獲得製造藥物製劑所需的原材料是運輸不規範造成的主要問題之一。 隨著患有 COVID-19 和其他危及生命的疾病的患者人數增加，分銷商也發現商店對其產品的需求不穩定。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第四章市場動態

  • 市場影響因素
    • 司機
      • 由於糖尿病足潰瘍的增加，擴張加速
      • 治療技術進步推動市場
    • 約束因素
      • 昂貴的高級傷口護理產品和療法限制了市場增長
    • 商機
    • 影響分析

第五章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 定價分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按潰瘍類型

  • 神經性潰瘍
  • 缺血性潰瘍
  • 神經缺血性潰瘍

第八章治療

  • 傷口敷料保護器
  • 生物製品
  • 其他

第 9 章最終用戶

  • 醫院
  • 專科診所
  • 長期護理中心
  • 門診手術中心
  • 家庭護理

第10章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第11章競爭格局

  • 主要發展和戰略
  • 公司股票分析
  • 產品基準
  • 值得關注的主要公司名單

第12章公司簡介

  • Medtronic
    • 公司簡介
    • 產品組合和說明
    • 主要亮點
    • 財務摘要
  • Organogenesis, Inc
  • Acelity L.P., Inc
  • B Braun Melsungen AG
  • Coloplast Corp
  • Medline Industries, Inc
  • 3M Healthcare
  • Molnlycke Health Care AB
  • Hyper oil
  • Smith & Nephew Plc.

第 13 章糖尿病神經性足部潰瘍的全球市場-DataM

簡介目錄
Product Code: DMPH28

Market Overview

Diabetic Neuropathic Foot Ulcers Market size was valued at US$ XX million in 2023 and is estimated to reach US$ XX million by 2030, growing at a CAGR of 8.4% during the forecast period (2023-2030).

The most frequent foot wounds resulting in lower extremity amputation are diabetic ulcers. General practitioners are crucial in the early detection or prevention of diabetic foot problems. The management of the diabetic foot necessitates in-depth familiarity with the primary amputation risk factors, routine evaluation, and meticulous preventive maintenance. The most frequent ulcer-forming risk factors include peripheral artery occlusive disease, structural foot deformity, and diabetic neuropathy.

Market Dynamics

The major factors driving the global diabetic neurotherapy foot ulcers market are the expansion is accelerated by the increasing number of diabetic foot ulcers, the market will be driven by treatment technology advancement and there are specific dressings available for a particular type of foot ulcer.

The expansion is accelerated by the increasing number of diabetic foot ulcers.

Patients with diabetes are prone to developing diabetic foot ulcers, which can necessitate the amputation of the leg. Patients with diabetes who use insulin to control their condition are more likely to develop a foot ulcer. In addition to diabetes, individuals with obesity, kidney, eye, and heart issues may also develop diabetic foot ulcers. Use of tobacco and alcohol both raises the risk of the illness.

According to the National Institutes of Health (U.S.A.), between 9.1 and 26.1 million diabetic foot ulcers occur annually over the world. In their lifetime, 15 to 25% of people with diabetes mellitus will get a diabetic foot ulcer. The prevalence of diabetic foot ulcers will inevitably rise as more people are diagnosed with diabetes each year. Although diabetic foot ulcers can develop at any age, they are most common in those with diabetes mellitus who are over 45. The majority of Americans with foot ulcers are Latinos, African Americans, and Native Americans. Thus, the growth is sped up by an increase in the incidence of diabetic foot ulcers.

Costly advanced wound care products and therapies of diabetic neurotherapy foot ulcers (DME) is expected to hamper the market's growth.

A diabetic foot ulcer is the most prevalent consequence of diabetes and a substantial cause of death. It is anticipated that ongoing technical developments in therapeutic alternatives will slow the market's growth because extracellular proteins, therapeutic agents, and other options have become too expensive.

COVID-19 Impact Analysis

The virus has spread to over 75 countries since the COVID-19 viral outbreak in December 2019, and the World Health Organization declared it a public health emergency. For instance, as of July 2021, about 190 million people worldwide were infected due to the coronavirus (COVID-19) manifestation, according to a study from the World Health Organization.

Three main ways that COVID-19 can affect the economy are directly altering supply and demand, disrupting distribution networks, and having an economic impact on businesses and financial markets. Many nations, including China, India, Saudi Arabia, the United Arab Emirates, Egypt, and others, have difficulty moving pharmaceuticals from one location to another due to widespread lockdowns. Furthermore, the COVID-19 pandemic poses significant obstacles for industry participants in the worldwide diabetic foot ulcer therapy market on numerous fronts. The availability of raw materials required to make pharmaceutical formulations is one of the major problems caused by transportation irregularities. Additionally, because of a rise in patients with COVID-19 and other life-threatening illnesses, distributors see irregular demand for their products from stores.

Segment Analysis

The wound care dressing diabetic Neurotherapy foot ulcers-type segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The advanced wound dressings segment dominated the market for treating diabetic foot ulcers worldwide. There are many kinds of hydrogel dressings for wound treatment, including alginate dressings, hydro fiber dressings, surgical dressings, and others. Foam dressings are the most popular type of wound care treatment nowadays. Patients who have non-healing wounds can benefit from advanced wound care dressings. It is an active non-woven wound dressing made entirely of natural biopolymer. The 360-degree, dynamic mode of action of wound care dressings allows for efficient discharge control, pain reduction, infection control, active wound healing, and scar improvement. The excellent absorption capacity and painless removal of wound care dressings enhance patient comfort. As a result, they are widely employed for the care of wounds in various phases, and key players are also releasing new products, which boosts the market for this category.

For instance, in October 2022, A new line of wound dressings named Theruptor Novo was introduced by Bengaluru-based Healthium Medtech for treating chronic wounds, including leg and foot ulcers caused by diabetes. With the introduction of Theruptor Novo, Healthium expands the range of proprietary solutions it already offers in the market for advanced wound dressings.

For instance, in September 2021, The American Company Human Biosciences (HBS) hinted that it would soon launch two wound care products in the Indian market. The two items have the names "Medifil" and "Skin Temp, according to an announcement from the company. The company plans to offer two of its wound care management products, "Medifil" and "Skin Temp" in India soon.

Geographical Analysis

North America holds the largest market share in the global diabetic neurotherapy foot ulcers market.

The most prevalent illness in this age range is diabetes, which frequently results in diabetic foot ulcers. The prevalence of diabetic foot ulcers has increased due to people living more sedentary lifestyles. In this region, diabetes affects one in two people, which has helped to increase the demand for diabetic foot ulcer treatments. The International Diabetes Federation 2021 estimates that 51 million people in North America and the Caribbean now have diabetes. More than 20 million Americans are thought to experience peripheral neuropathy. However, given that not everyone who displays neuropathy symptoms is tested for the condition and that tests are currently not developed to detect all forms of neuropathy, this number may be much higher.

Major market competitors, rising healthcare GDP spending, and enhanced reimbursement for DFU therapy primarily influence the region's market growth. According to the Canadian Diabetes Association 2020, diabetes accounts for 70% of lower limb amputations carried out in hospitals and are the most common reason for non-traumatic lower limb amputation in Canadian adults. Canadian individuals with diabetes are nearly 20 times more likely than the general population to have non-traumatic lower limb amputations, 85% of which are preceded by a foot ulcer.

Competitive Landscape

The diabetic neurotherapy foot ulcers market is moderately competitive with local and global companies' presence Medtronic, Organogenesis, Inc, Acelity L.P., Inc, B Braun Melsungen AG, Coloplast Corp, Smith & Nephew Plc, Medline Industries, Inc, 3M Healthcare, Molnlycke Health Care AB, Hyper oil and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in June 2022, Smith + Nephew will spend over $100 million to build a top-notch research and development, manufacturing, and flexible office building. A funding from the UK government will also help to fund the development. In its first ten years of operation, the new factory is anticipated to support sales of more than $10 billion.

Hyper Oil.

Overview: The product's patent license was obtained by RI.MOS in 2005, and clinical trials for the treatment of ulcers and bedsores in humans commenced in 2006. Even the most hopeful predictions were surpassed by the initial results of the Clinica Barbantini of Lucca, Tuscany, one of the most significant National reference centers, conducted by the Department of Vulnology. Holoil (a brand for the Italian market) and Hyperoil (a brand for international markets) received CE approval as Class IIb Medical Devices in 2008. In 2009, RI.MOS launched the Hypermix for Veterinary Use and Holoil for Human Use brands to promote the product in the Italian market (in 2011).

Product Portfolio:

Fast Healing Advanced Wound Dressing: Infection prevention, re-epithelialization support, fibrinolytic action, and other benefits are provided by hyperoil. At all stages of tissue repair, it only needs the assistance of secondary dressings to protect and/or absorb, as necessary, while carrying out all other essential tasks on its own.

The global diabetic neurotherapy foot ulcers market report would provide access to approx.: 45 + market data table, 40 + figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The expansion is accelerated by the increasing number of diabetic foot ulcers
      • 4.1.1.2. The market will be driven by treatment technology advancement
    • 4.1.2. Restraints:
      • 4.1.2.1. Costly advanced wound care products and therapies restrain market expansion
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis
  • 5.4 Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Ulcer Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ulcer Type
    • 7.1.2. Market Attractiveness Index, By Ulcer Type
  • 7.2. Neuropathic Ulcers
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Ischemic Ulcers
  • 7.4. Neuro-Ischemic Ulcers

8. By Treatment Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.1.2. Market Attractiveness Index, By Treatment Type
  • 8.2. Wound Care Dressings
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Biologics
  • 8.4. Others

9. By End user

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 9.1.2. Market Attractiveness Index, By End user
  • 9.2. Hospitals
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Specialty Clinics
  • 9.4. Long term Care Centres
  • 9.5. Ambulatory Surgical Centres
  • 9.6. Home Care setting

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size AnalysisUS$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ulcer Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ulcer Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ulcer Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ulcer Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ulcer Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Products Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. Medtronic
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Organogenesis, Inc
  • 12.3. Acelity L.P., Inc
  • 12.4. B Braun Melsungen AG
  • 12.5. Coloplast Corp
  • 12.6. Medline Industries, Inc
  • 12.7. 3M Healthcare
  • 12.8. Molnlycke Health Care AB
  • 12.9. Hyper oil
  • 12.10. Smith & Nephew Plc.

LIST NOT EXHAUSTIVE

13. Global Diabetic Neurotherapy Foot Ulcers Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Application
  • 13.3. Contact Us